Michael B. Foote

Oncology

300 E 66th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

ASO Visual Abstract: Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.

ASO Visual Abstract: Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.

Journal: Annals of surgical oncology

Published: March 02, 2026

ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases.

ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases.

Journal: Annals of surgical oncology

Published: February 24, 2026

ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.

ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.

Journal: Annals of surgical oncology

Published: February 03, 2026

Molecular Lineages of Sporadic Mismatch Repair-Deficient Colorectal Cancer.

Molecular Lineages of Sporadic Mismatch Repair-Deficient Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 03, 2026

Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.

Incidence and Predictors of Neoplastic Diagnosis in Patients with a Clinically Abnormal Appendix.

Journal: Annals of surgical oncology

Published: October 24, 2025

Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases.

Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases.

Journal: Annals of surgical oncology

Published: September 24, 2025

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

Journal: Cancer cell

Published: September 18, 2025

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Journal: Research square

Published: September 15, 2025

Genomics correlates of brain metastasis and progression in colorectal cancer.

Genomics correlates of brain metastasis and progression in colorectal cancer.

Journal: Neuro-oncology

Published: September 02, 2025

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Journal: Nature medicine

Published: August 09, 2025

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 18, 2025

Clonal hematopoiesis detection by simultaneous assessment of peripheral blood mononuclear cells, blood plasma, and saliva.

Clonal hematopoiesis detection by simultaneous assessment of peripheral blood mononuclear cells, blood plasma, and saliva.

Journal: The Journal of clinical investigation

Published: June 19, 2025

Showing 1-12 of 69

Last Updated: 09/26/2026